571 related articles for article (PubMed ID: 33845029)
1. Methadone and buprenorphine discontinuation among postpartum women with opioid use disorder.
Schiff DM; Nielsen TC; Hoeppner BB; Terplan M; Hadland SE; Bernson D; Greenfield SF; Bernstein J; Bharel M; Reddy J; Taveras EM; Kelly JF; Wilens TE
Am J Obstet Gynecol; 2021 Oct; 225(4):424.e1-424.e12. PubMed ID: 33845029
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Racial and Ethnic Disparities in the Use of Medication to Treat Opioid Use Disorder Among Pregnant Women in Massachusetts.
Schiff DM; Nielsen T; Hoeppner BB; Terplan M; Hansen H; Bernson D; Diop H; Bharel M; Krans EE; Selk S; Kelly JF; Wilens TE; Taveras EM
JAMA Netw Open; 2020 May; 3(5):e205734. PubMed ID: 32453384
[TBL] [Abstract][Full Text] [Related]
3. Availability of Medications for the Treatment of Opioid Use Disorder Among Pregnant and Postpartum Individuals in US Jails.
Sufrin C; Kramer CT; Terplan M; Fiscella K; Olson S; Voegtline K; Latkin C
JAMA Netw Open; 2022 Jan; 5(1):e2144369. PubMed ID: 35050354
[TBL] [Abstract][Full Text] [Related]
4. Medication assisted treatment discontinuation in pregnant and postpartum women with opioid use disorder.
Wilder C; Lewis D; Winhusen T
Drug Alcohol Depend; 2015 Apr; 149():225-31. PubMed ID: 25735465
[TBL] [Abstract][Full Text] [Related]
5. Racial and Ethnic Inequities in Buprenorphine and Methadone Utilization Among Reproductive-Age Women with Opioid Use Disorder: an Analysis of Multi-state Medicaid Claims in the USA.
Xu KY; Schiff DM; Jones HE; Martin CE; Kelly JC; Bierut LJ; Carter EB; Grucza RA
J Gen Intern Med; 2023 Dec; 38(16):3499-3508. PubMed ID: 37436568
[TBL] [Abstract][Full Text] [Related]
6. Use of naltrexone in treating opioid use disorder in pregnancy.
Towers CV; Katz E; Weitz B; Visconti K
Am J Obstet Gynecol; 2020 Jan; 222(1):83.e1-83.e8. PubMed ID: 31376396
[TBL] [Abstract][Full Text] [Related]
7. Fatal and Nonfatal Overdose Among Pregnant and Postpartum Women in Massachusetts.
Schiff DM; Nielsen T; Terplan M; Hood M; Bernson D; Diop H; Bharel M; Wilens TE; LaRochelle M; Walley AY; Land T
Obstet Gynecol; 2018 Aug; 132(2):466-474. PubMed ID: 29995730
[TBL] [Abstract][Full Text] [Related]
8. Racial and Ethnic Disparities in Maternal and Infant Outcomes Among Opioid-Exposed Mother-Infant Dyads in Massachusetts (2017-2019).
Peeler M; Gupta M; Melvin P; Bryant AS; Diop H; Iverson R; Callaghan K; Wachman EM; Singh R; Houghton M; Greenfield SF; Schiff DM
Am J Public Health; 2020 Dec; 110(12):1828-1836. PubMed ID: 33058701
[No Abstract] [Full Text] [Related]
9. Postpartum medication for opioid use disorder outcomes associated with prenatal treatment and neighborhood-level social determinants.
Martin CE; Britton E; Shadowen H; Johnson J; Sabo R; Cunningham P
Am J Obstet Gynecol MFM; 2023 Nov; 5(11):101173. PubMed ID: 37783277
[TBL] [Abstract][Full Text] [Related]
10. Characteristics and Receipt of Medication Treatment Among Young Adults Who Experience a Nonfatal Opioid-Related Overdose.
Bagley SM; Larochelle MR; Xuan Z; Wang N; Patel A; Bernson D; Silverstein M; Hadland SE; Land T; Samet JH; Walley AY
Ann Emerg Med; 2020 Jan; 75(1):29-38. PubMed ID: 31591014
[TBL] [Abstract][Full Text] [Related]
11. Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine.
Park TW; Larochelle MR; Saitz R; Wang N; Bernson D; Walley AY
Addiction; 2020 May; 115(5):924-932. PubMed ID: 31916306
[TBL] [Abstract][Full Text] [Related]
12. Initiation and Treatment Discontinuation of Medications for Opioid Use Disorder in Pregnant People Compared With Nonpregnant People.
Xu KY; Jones HE; Schiff DM; Martin CE; Kelly JC; Carter EB; Bierut LJ; Grucza RA
Obstet Gynecol; 2023 Apr; 141(4):845-853. PubMed ID: 36897142
[TBL] [Abstract][Full Text] [Related]
13. "You have to take this medication, but then you get punished for taking it:" lack of agency, choice, and fear of medications to treat opioid use disorder across the perinatal period.
Schiff DM; Work EC; Muftu S; Partridge S; MacMillan KDL; Gray JR; Hoeppner BB; Kelly JF; Greenfield SF; Jones HE; Wilens TE; Terplan M; Bernstein J
J Subst Abuse Treat; 2022 Aug; 139():108765. PubMed ID: 35341614
[TBL] [Abstract][Full Text] [Related]
14. Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data.
Zhang P; Tossone K; Ashmead R; Bickert T; Bailey E; Doogan NJ; Mack A; Schmidt S; Bonny AE
J Subst Abuse Treat; 2022 May; 136():108686. PubMed ID: 34953637
[TBL] [Abstract][Full Text] [Related]
15. Outcomes associated with the use of medications for opioid use disorder during pregnancy.
Krans EE; Kim JY; Chen Q; Rothenberger SD; James AE; Kelley D; Jarlenski MP
Addiction; 2021 Dec; 116(12):3504-3514. PubMed ID: 34033170
[TBL] [Abstract][Full Text] [Related]
16. A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia.
Burns L; Gisev N; Larney S; Dobbins T; Gibson A; Kimber J; Larance B; Mattick RP; Butler T; Degenhardt L
Addiction; 2015 Apr; 110(4):646-55. PubMed ID: 25516077
[TBL] [Abstract][Full Text] [Related]
17. Treating Women Who Are Pregnant and Parenting for Opioid Use Disorder and the Concurrent Care of Their Infants and Children: Literature Review to Support National Guidance.
Klaman SL; Isaacs K; Leopold A; Perpich J; Hayashi S; Vender J; Campopiano M; Jones HE
J Addict Med; 2017; 11(3):178-190. PubMed ID: 28406856
[TBL] [Abstract][Full Text] [Related]
18. Duration of medication for opioid use disorder during pregnancy and postpartum by race/ethnicity: Results from 6 state Medicaid programs.
Austin AE; Durrance CP; Ahrens KA; Chen Q; Hammerslag L; McDuffie MJ; Talbert J; Lanier P; Donohue JM; Jarlenski M
Drug Alcohol Depend; 2023 Jun; 247():109868. PubMed ID: 37058829
[TBL] [Abstract][Full Text] [Related]
19. Drug use patterns and factors related to the use and discontinuation of medications for opioid use disorder in the age of fentanyl: findings from a mixed-methods study of people who use drugs.
Hughto JMW; Tapper A; Rapisarda SS; Stopka TJ; Palacios WR; Case P; Silcox J; Moyo P; Green TC
Subst Abuse Treat Prev Policy; 2023 May; 18(1):30. PubMed ID: 37217975
[TBL] [Abstract][Full Text] [Related]
20. Differences in the delivery of medications for opioid use disorder during hospitalization by racial categories: A retrospective cohort analysis.
Priest KC; King CA; Englander H; Lovejoy TI; McCarty D
Subst Abus; 2022; 43(1):1251-1259. PubMed ID: 35670778
[No Abstract] [Full Text] [Related]
[Next] [New Search]
